Pepdexpepdex
Stack
← All compounds

BP & lipid meds (cycle support)

Telmisartan, Nebivolol, Hydrochlorothiazide / HCTZ, Ezetimibe, Bempedoic acid · Cardiovascular prescription drugs

Research reference only. Pepdex does not sell, supply or track this compound, and nothing here is guidance to use it — this page exists so the evidence and the risks are visible.

What it is

Real cardiology drugs — blood-pressure agents (telmisartan, nebivolol, HCTZ) and non-statin lipid drugs (ezetimibe, bempedoic acid) — that circulate in AAS contexts as "cycle support" for the hypertension and lipid damage steroids cause.

How it works

This entry covers the cardiovascular prescription drugs — statins, blood-pressure medicines, and others — that circulate in performance communities as "cycle support", taken to offset the cardiovascular damage anabolic steroids cause. Each of these drugs has a real mechanism and real evidence for its approved use. The framing is what this entry is about: using a prescription cardiac drug to manage the harm of an ongoing illicit exposure is a fundamentally different proposition from treating a diagnosed condition, and it has never been studied.

What human evidence shows

Each is well-evidenced for its cardiology indication. The problem is the delivery model: self-prescribing antihypertensives to enable an ongoing harm inverts the logic of treatment.

The studies, one by one

  • STRONG for each drug in its own approved indication — statins for lipid management and cardiovascular risk reduction, antihypertensives for blood pressure, on very large trial programmes.
  • NONE SHOWN for the cycle-support use. No trial has tested whether taking a statin alongside anabolic steroids prevents the cardiovascular harm those steroids cause, and there is no basis for assuming it does.
  • The specific concern is that these drugs treat measured numbers, and the steroid-associated cardiac harm that imaging studies find — impaired ventricular function, accelerated coronary plaque — is not a number a statin normalises. A better lipid panel on an ongoing steroid exposure is not evidence of a protected heart.
  • Some of these drugs carry their own interaction risk with steroids: anabolic steroids can substantially potentiate coumarin anticoagulants, which is a documented major interaction.
  • Obtaining prescription cardiac drugs outside a prescriber relationship means no diagnosis, no monitoring, and no one adjusting anything when something changes.

Half-life and how long it lasts

These are established prescription medicines with characterised pharmacology in their approved settings. What is not characterised is their behaviour alongside supraphysiologic androgens, which alter lipids, blood pressure, red cell mass and clotting through mechanisms these drugs were not designed around.

Risks

Unmonitored use means nobody is checking kidney function, electrolytes (HCTZ specifically), or whether pressure is actually controlled — a number on a home cuff is not a workup. Treating blood pressure or lipids may reduce specific risks but does not remove the other cardiovascular harms of ongoing AAS exposure. If blood pressure or lipids need medicating, that is a physician conversation — this entry exists so the names resolve, not to bless the practice.

Who should never touch it

  • Anyone taking prescription cardiac medication without a prescriber, a diagnosis or monitoring
  • Anyone using it as a reason to continue an exposure that is causing the problem
  • Anyone combining anticoagulants with anabolic steroids, given the documented major interaction

Interactions worth knowing

  • Anabolic steroids and coumarin anticoagulants — a documented major interaction where steroids substantially potentiate the anticoagulant effect.
  • Statins and several other cardiac drugs share liver metabolism pathways with compounds commonly stacked alongside them.
  • Multiple prescription drugs taken without a prescriber, where no one is checking the combination at all.

What a clinician would watch

  • Anyone taking cardiac medication needs a clinician managing it — that is the whole point of the category, and it is what the cycle-support framing removes.
  • Tell any clinician what you are actually taking, including the steroids. Managing cardiovascular risk without that information is guesswork on their part.
  • Class-level severe outcomes reported with anabolic steroids remain regardless of what is taken alongside them: cardiac arrest, heart attack, thickened heart muscle, heart failure and stroke.
  • Chest pain, breathlessness, leg swelling or fainting are urgent assessment, not signals to adjust a supporting drug.

What stopping looks like

Stopping a prescription cardiac drug is a decision for the clinician who prescribed it — abrupt discontinuation of some blood-pressure medicines causes rebound effects. For anyone taking them without a prescriber, the more useful step is the opposite direction: getting an actual cardiovascular assessment, and disclosing everything being taken, so that decisions rest on something better than assumption.

Myth vs evidence

“Cycle support protects your heart.”

No trial has tested that. These drugs treat measured numbers; the cardiac remodelling and coronary plaque found in imaging studies of long-term users are not numbers a supporting drug normalises.

“Normal bloodwork on cycle means the heart is fine.”

That is the central error. Imaging studies find impaired ventricular function and coronary plaque in users whose routine labs did not reveal it.

“These are safe drugs, so adding them is low risk.”

They are safe when prescribed for a diagnosed condition with monitoring. Taken without either, alongside compounds that alter the same systems, that safety record does not transfer.

Legal status

US: all prescription-only. Products outside licensed dispensing are unapproved.

Research on this compound

Papers about this compound, not proof of the claims above. A title says what was studied, which is sometimes a negative result or a different question entirely.

  • Telmisartan Improves Insulin Resistance: A Meta-Analysis
    Am J Ther, 2018
  • Telmisartan improves insulin sensitivity: a meta-analysis of randomized head-to-head trials
    Int J Cardiol, 2012
  • Telmisartan increases adiponectin levels: a meta-analysis and meta-regression of randomized head-to-head trials
    Int J Cardiol, 2012

Evidence base

Not auto-graded. This entry covers several different drugs, or a use the published research was never about, so no single letter honestly describes it. The reading below is real literature — read it against what this page says, not as a score.

Research (12)

Turn BP & lipid meds (cycle support) into a plan that's yours

The info above is free. Membership makes it personal, the Coach answers questions about your exact stack, the Stack tracks it for you, and the Verified Sources shows you how to vet what you buy.

  • ✓ AI Coach, ask anything about your stack. It does the dosing math, flags interactions, and tells you what to do next.
  • ✓ Personal Stack, save your protocol, track it across devices, log doses, get a heads-up before a vial runs out.
  • ✓ Verified Sources, the vetted reference for checking quality and sourcing, members only.
Become a member, from $4.99/week

Cancel anytime · or save with $59.99/yr · Coach + Stack included

Where next

Every compound in the catalogThe full non-peptide index, with evidence grades.→The peptide indexInjectable peptides, half-lives and what trials used.→Spotting a scam vendorRed flags, COA checks and what traceability looks like.→